Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.92 USD | -3.52% | -3.64% | -15.65% |
07:24pm | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.65% | 1.22B | |
+18.27% | 47.02B | |
+48.77% | 41.86B | |
+0.51% | 41.76B | |
-4.27% | 28.8B | |
+11.83% | 26.05B | |
-21.93% | 19.15B | |
+4.25% | 12.55B | |
+28.75% | 12.34B | |
-4.17% | 11.82B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating